Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Solomon

Showing results (1181-1190 of 1,873) with videos related to

Pageof 188
Sort By:
European Journal of Heart Failure|May 15, 2026
Iron deficiency and risk of heart failure and cardiovascular events in CKD: Insights from the ASCEND-ND trialBrendon L Neuen, Henri Lu, Muthiah Vaduganathan, et al.
Diabetes, Obesity & Metabolism|October 30, 2015
Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trialH J L Heerspink, T Ninomiya, F Persson, et al.
European Journal of Heart Failure|June 7, 2017
Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) studyGerasimos Filippatos, Aldo P Maggioni, Carolyn S P Lam, et al.
European Journal of Heart Failure|October 28, 2022
Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trialsJoão Pedro Ferreira, John G Cleland, Nicolas Girerd, et al.
European Journal of Heart Failure|January 19, 2013
Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF)John J V McMurray, Inder S Anand, Rafael Diaz, et al.
JACC. Heart Failure|September 8, 2014
Heart failure risk across the spectrum of ankle-brachial index: the ARIC study (Atherosclerosis Risk In Communities)Deepak K Gupta, Hicham Skali, Brian Claggett, et al.
Cardiovascular Diabetology|June 18, 2022
Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trialsMagnus O Wijkman, Brian Claggett, Muthiah Vaduganathan, et al.
Circulation. Heart Failure|March 16, 2019
N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation StatusSøren L Kristensen, Ulrik M Mogensen, Pardeep S Jhund, et al.
The New England Journal of Medicine|November 6, 2012
Cardiorenal end points in a trial of aliskiren for type 2 diabetesHans-Henrik Parving, Barry M Brenner, John J V McMurray, et al.
European Journal of Neurology|November 21, 2024
Association of left atrial function with vascular brain injury: The Atherosclerosis Risk in Communities studyWendy Wang, Pamela L Lutsey, Riccardo M Inciardi, et al.
Pageof 188

Showing results (1181-1190 of 1,873) with videos related to

Sort By:
Pageof 188
European Journal of Heart Failure|May 15, 2026
Iron deficiency and risk of heart failure and cardiovascular events in CKD: Insights from the ASCEND-ND trialBrendon L Neuen, Henri Lu, Muthiah Vaduganathan, et al.
Diabetes, Obesity & Metabolism|October 30, 2015
Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trialH J L Heerspink, T Ninomiya, F Persson, et al.
European Journal of Heart Failure|June 7, 2017
Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) studyGerasimos Filippatos, Aldo P Maggioni, Carolyn S P Lam, et al.
European Journal of Heart Failure|October 28, 2022
Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trialsJoão Pedro Ferreira, John G Cleland, Nicolas Girerd, et al.
European Journal of Heart Failure|January 19, 2013
Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF)John J V McMurray, Inder S Anand, Rafael Diaz, et al.
JACC. Heart Failure|September 8, 2014
Heart failure risk across the spectrum of ankle-brachial index: the ARIC study (Atherosclerosis Risk In Communities)Deepak K Gupta, Hicham Skali, Brian Claggett, et al.
Cardiovascular Diabetology|June 18, 2022
Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trialsMagnus O Wijkman, Brian Claggett, Muthiah Vaduganathan, et al.
Circulation. Heart Failure|March 16, 2019
N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation StatusSøren L Kristensen, Ulrik M Mogensen, Pardeep S Jhund, et al.
The New England Journal of Medicine|November 6, 2012
Cardiorenal end points in a trial of aliskiren for type 2 diabetesHans-Henrik Parving, Barry M Brenner, John J V McMurray, et al.
European Journal of Neurology|November 21, 2024
Association of left atrial function with vascular brain injury: The Atherosclerosis Risk in Communities studyWendy Wang, Pamela L Lutsey, Riccardo M Inciardi, et al.
Pageof 188